Ekso Bionics Holding ((EKSO)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ekso Bionics is conducting a clinical study titled ‘Health and Financial Impact on the Use of a Personal Exoskeleton in the Home and Community: a Case Study.’ The study aims to assess the long-term use of a personal overground robotic exoskeleton in individuals with spinal cord injury. Key objectives include evaluating usage patterns, health outcomes such as heart rate and physical activity, and healthcare expenditures over a 12-month period. This research is significant as it explores the potential health and financial benefits of exoskeleton technology in real-world settings.
The intervention being tested is the ‘Overground Robotic Exoskeleton,’ specifically the Ekso Indego Personal device. This device is intended to assist individuals with spinal cord injury by enabling mobility in home and community environments, potentially improving health outcomes and reducing healthcare costs.
The study is observational in design, following a cohort model with a prospective time perspective. Participants will use the exoskeleton at their discretion after receiving training, with no specific usage requirements. The primary purpose is to observe the impact of the device on health and financial metrics over time.
The study began on May 30, 2025, with the last update submitted on August 4, 2025. These dates are crucial as they indicate the study’s current phase and progress. The primary completion and estimated completion dates have not been specified, highlighting that the study is ongoing.
For investors, this study update could signal potential growth opportunities for Ekso Bionics if the results demonstrate significant health and financial benefits. Positive outcomes could enhance investor sentiment and influence stock performance, especially in comparison to competitors in the exoskeleton market. The study’s findings may also impact broader industry trends regarding the adoption of robotic exoskeletons.
The study is currently ongoing, with further details available on the ClinicalTrials portal.